You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

phosphatidylinositol 3-kinase δ (PI3Kδ) inhibitor

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Metastatic Breast Cancer Trial in East Melbourne (BYl719)

Completed
  • Metastatic Breast Cancer
  • East Melbourne, Victoria, Australia
    Peter MacCallum Cancer Centre
Aug 11, 2022

Activated PI3K-delta Syndrome, Immunodeficiency Primary Trial in Shanghai (Rapamycin)

Recruiting
  • Activated PI3K-delta Syndrome
  • Immunodeficiency Primary
  • Shanghai, Shanghai, China
  • +1 more
Mar 21, 2022

Cushing Disease Trial (Fimepinostat)

Not yet recruiting
  • Cushing Disease
  • (no location specified)
Jul 31, 2023

PI3Kd Inhibitor, Parsaclisib, CHOP Trial (Parsaclisib, CHOP)

Not yet recruiting
  • PI3Kδ Inhibitor
  • +3 more
  • (no location specified)
Feb 10, 2022

Mantle Cell Lymphoma Trial (parsaclisib, rituximab, bendamustine)

Withdrawn
  • Mantle Cell Lymphoma
  • (no location specified)
Apr 22, 2022

Peripheral T-Cell Lymphoma Trial in Zhengzhou (Parsaclisib, Chidamide)

Not yet recruiting
  • Peripheral T-Cell Lymphoma
  • Zhengzhou, Henan, China
    Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZho
Dec 26, 2021

Indolent Non-hodgkin Lymphoma Trial in Shanghai (IBI376)

Active, not recruiting
  • Indolent Non-hodgkin Lymphoma
  • Shanghai, China
    Ruijin hospital, school of medicine, Shanghai jiao tong universi
Oct 3, 2022

Locally Advanced Breast Cancer, Metastatic Breast Cancer Trial in Batumi, Tbilisi (Tenalisib)

Active, not recruiting
  • Locally Advanced Breast Cancer
  • Metastatic Breast Cancer
  • Batumi, Georgia
  • +2 more
May 2, 2022

Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer Trial in Miami (AI+CDK4/6i, SERD+CDK4/6i, mTOR inhibitor +

Not yet recruiting
  • Breast Cancer
  • +3 more
  • Miami, Florida
    University of Miami
Apr 12, 2023

Mantle Cell Lymphoma Trial in Duarte (Acalabrutinib, Ublituximab, Umbralisib)

Suspended
  • Mantle Cell Lymphoma
  • Duarte, California
    City of Hope Medical Center
Jun 7, 2022

Activated PI3Kdelta Syndrome (APDS); PASLI Disease Trial in Worldwide (CDZ173)

Active, not recruiting
  • Activated PI3Kdelta Syndrome (APDS); PASLI Disease
  • Bethesda, Maryland
  • +7 more
Jul 22, 2022

Inert Non Hodgkin's Lymphoma Trial in Beijing (IBI376, Rituximab)

Recruiting
  • Inert Non Hodgkin's Lymphoma
  • Beijing, China
    Biotherapeutic Department, Chinese PLA General Hospital
Feb 19, 2022

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Follicular Lymphoma Trial in Australia, China (BGB-10188,

Recruiting
  • Chronic Lymphocytic Leukemia
  • +9 more
  • Adelaide, Australia
  • +12 more
Jan 6, 2023

Follicular Lymphoma Trial in Germany (Copanlisib, Obinutuzumab)

Recruiting
  • Follicular Lymphoma
  • München, Bavaria, Germany
  • +39 more
May 19, 2022

Solid Tumor, Adult, Non-Hodgkin Lymphoma, Adult, NSCLC Trial in Rozzano, Siena, Glasgow (IOA-244, Avelumab Injection,

Recruiting
  • Solid Tumor, Adult
  • +4 more
  • Rozzano, Milan, Italy
  • +2 more
May 13, 2022

Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Invasive Ductal Breast Carcinoma Trial in Boston,

Active, not recruiting
  • Estrogen Receptor-positive Breast Cancer
  • +5 more
  • PI3K inhibitor BYL719
  • +3 more
  • Boston, Massachusetts
  • +1 more
Oct 14, 2022

Locally Advanced Malignant Solid Tumor, Metastatic Malignant Tumor in the Bone, Metastatic Malignant Solid Tumor Trial

Withdrawn
  • Locally Advanced Malignant Solid Neoplasm
  • +3 more
  • (no location specified)
May 24, 2022

Colorectal Cancer, Gastric Cancer, HER2-negative Breast Cancer Trial (TOS-358)

Not yet recruiting
  • Colorectal Cancer
  • +8 more
  • (no location specified)
Jan 5, 2023

Safety Issues, Efficacy, Self Trial in Beijing (TQB3525)

Active, not recruiting
  • Safety Issues
  • Efficacy, Self
  • Beijing, China
    Peking University Shougang Hospital
Dec 29, 2020

Healthy Trial in Nottingham ([14C]-Paxalisib Capsule)

Active, not recruiting
  • Healthy
  • [14C]-Paxalisib Capsule
  • Nottingham, United Kingdom
    Quotient Sciences
Aug 16, 2022

Brain and CNS Tumors Trial in Memphis (GDC-0084, radiation therapy)

Completed
  • Brain and Central Nervous System Tumors
  • Memphis, Tennessee
    St. Jude Children's Research Hospital
Jan 13, 2023

Chronic Lymphocytic Leukemia, DLBCL, Follicular Lymphoma Trial in Duarte, Boston, Portland (Copanlisib, Nivolumab)

Recruiting
  • Chronic Lymphocytic Leukemia
  • +6 more
  • Duarte, California
  • +2 more
Mar 9, 2022

Advanced Hepatocellular Carcinoma Trial in La Jolla (SF1126, Nivolumab)

Terminated
  • Advanced Hepatocellular Carcinoma
  • La Jolla, California
    UC San Diego Moores Cancer Center
May 11, 2022

Mixed Tumor, Malignant Trial in United States (BAY806946)

Recruiting
  • Mixed Tumor, Malignant
  • Birmingham, Alabama
  • +20 more
Jan 20, 2023

Non Hodgkin Lymphoma Trial in Australia, United States (Tenalisib,)

Completed
Has Results
  • Non Hodgkin Lymphoma
  • Huntsville, Alabama
  • +11 more
Jul 20, 2021